Understanding how lung cancer treatments work in Latino and Asian patients
Characterizing treatment responses for common lung cancer (LC) subtypes in Latinos and Asians
This study is looking for genetic clues that can help us understand why some people with lung cancer, especially those with EGFR mutations in Latino and Asian communities, respond differently to certain treatments, so we can create better ways to help everyone fight the disease.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project ID | NIH-10896249 on NIH RePORTER |
What this research studies
This research focuses on identifying genetic markers that indicate resistance to specific lung cancer treatments in patients with EGFR mutations, particularly among Latino and Asian populations. By analyzing how race, ethnicity, and genetic ancestry influence treatment responses, the study aims to develop better therapeutic strategies that combine existing FDA-approved drugs. Patients will be involved in clinical trials that test these new approaches to improve treatment outcomes for lung cancer. The research will also explore the biological factors that contribute to differences in treatment efficacy among diverse populations.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with EGFR-mutant non-small cell lung cancer, particularly those of Latino or Asian descent.
Not a fit: Patients with lung cancer who do not have EGFR mutations or those from other ethnic backgrounds may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized lung cancer treatments for Latino and Asian patients.
How similar studies have performed: Previous research has shown promising results in targeting genetic markers for treatment resistance in lung cancer, indicating that this approach has potential for success.
Where this research is happening
Davis, United States
- University of California at Davis — Davis, United States (Active)
Researchers
- Principal investigator: Riess, Jonathan W — University of California at Davis
- Study coordinator: Riess, Jonathan W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.